318 related articles for article (PubMed ID: 12740129)
1. Synaptic plasticity in animal models of early Alzheimer's disease.
Rowan MJ; Klyubin I; Cullen WK; Anwyl R
Philos Trans R Soc Lond B Biol Sci; 2003 Apr; 358(1432):821-8. PubMed ID: 12740129
[TBL] [Abstract][Full Text] [Related]
2. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies.
Rowan MJ; Klyubin I; Wang Q; Anwyl R
Biochem Soc Trans; 2005 Aug; 33(Pt 4):563-7. PubMed ID: 16042545
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity.
Rowan MJ; Klyubin I; Wang Q; Anwyl R
Exp Gerontol; 2004; 39(11-12):1661-7. PubMed ID: 15582282
[TBL] [Abstract][Full Text] [Related]
4. Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo.
Hu NW; Smith IM; Walsh DM; Rowan MJ
Brain; 2008 Sep; 131(Pt 9):2414-24. PubMed ID: 18678563
[TBL] [Abstract][Full Text] [Related]
5. Non-fibrillar beta-amyloid abates spike-timing-dependent synaptic potentiation at excitatory synapses in layer 2/3 of the neocortex by targeting postsynaptic AMPA receptors.
Shemer I; Holmgren C; Min R; Fülöp L; Zilberter M; Sousa KM; Farkas T; Härtig W; Penke B; Burnashev N; Tanila H; Zilberter Y; Harkany T
Eur J Neurosci; 2006 Apr; 23(8):2035-47. PubMed ID: 16630051
[TBL] [Abstract][Full Text] [Related]
6. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide-induced dysfunction.
Rowan MJ; Klyubin I; Wang Q; Hu NW; Anwyl R
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1219-23. PubMed ID: 17956317
[TBL] [Abstract][Full Text] [Related]
7. Arginine vasopressin prevents amyloid beta protein-induced impairment of long-term potentiation in rat hippocampus in vivo.
Jing W; Guo F; Cheng L; Zhang JF; Qi JS
Neurosci Lett; 2009 Feb; 450(3):306-10. PubMed ID: 19059464
[TBL] [Abstract][Full Text] [Related]
8. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.
Trinchese F; Liu S; Battaglia F; Walter S; Mathews PM; Arancio O
Ann Neurol; 2004 Jun; 55(6):801-14. PubMed ID: 15174014
[TBL] [Abstract][Full Text] [Related]
9. [Effects of amyloid β-protein on hippocampal long-term potentiation].
Zhang JF; Yang D; Qi JS
Sheng Li Xue Bao; 2010 Dec; 62(6):479-88. PubMed ID: 21170492
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer amyloid beta-peptide A-beta25-35 blocks adenylate cyclase-mediated forms of hippocampal long-term potentiation.
Bisel BE; Henkins KM; Parfitt KD
Ann N Y Acad Sci; 2007 Feb; 1097():58-63. PubMed ID: 17413011
[TBL] [Abstract][Full Text] [Related]
11. A case for a non-transgenic animal model of Alzheimer's disease.
Stéphan A; Phillips AG
Genes Brain Behav; 2005 Apr; 4(3):157-72. PubMed ID: 15810904
[TBL] [Abstract][Full Text] [Related]
12. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.
Klyubin I; Walsh DM; Lemere CA; Cullen WK; Shankar GM; Betts V; Spooner ET; Jiang L; Anwyl R; Selkoe DJ; Rowan MJ
Nat Med; 2005 May; 11(5):556-61. PubMed ID: 15834427
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo.
Zhang JF; Qi JS; Qiao JT
Neurobiol Learn Mem; 2009 Mar; 91(3):226-34. PubMed ID: 19061963
[TBL] [Abstract][Full Text] [Related]
14. APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy.
Breyhan H; Wirths O; Duan K; Marcello A; Rettig J; Bayer TA
Acta Neuropathol; 2009 Jun; 117(6):677-85. PubMed ID: 19387667
[TBL] [Abstract][Full Text] [Related]
15. Chronic psychosocial stress exacerbates impairment of cognition and long-term potentiation in beta-amyloid rat model of Alzheimer's disease.
Srivareerat M; Tran TT; Alzoubi KH; Alkadhi KA
Biol Psychiatry; 2009 Jun; 65(11):918-26. PubMed ID: 18849021
[TBL] [Abstract][Full Text] [Related]
16. Inverse correlation between amyloid precursor protein and synaptic plasticity in transgenic mice.
Matsuyama S; Teraoka R; Mori H; Tomiyama T
Neuroreport; 2007 Jul; 18(10):1083-7. PubMed ID: 17558301
[TBL] [Abstract][Full Text] [Related]
17. LPYFDa neutralizes amyloid-beta-induced memory impairment and toxicity.
Granic I; Masman MF; Kees Mulder C; Nijholt IM; Naude PJ; de Haan A; Borbély E; Penke B; Luiten PG; Eisel UL
J Alzheimers Dis; 2010; 19(3):991-1005. PubMed ID: 20157254
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's disease: Abeta, tau and synaptic dysfunction.
LaFerla FM; Oddo S
Trends Mol Med; 2005 Apr; 11(4):170-6. PubMed ID: 15823755
[TBL] [Abstract][Full Text] [Related]
19. Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies.
Kirkitadze MD; Bitan G; Teplow DB
J Neurosci Res; 2002 Sep; 69(5):567-77. PubMed ID: 12210822
[TBL] [Abstract][Full Text] [Related]
20. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.
Walsh DM; Klyubin I; Shankar GM; Townsend M; Fadeeva JV; Betts V; Podlisny MB; Cleary JP; Ashe KH; Rowan MJ; Selkoe DJ
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1087-90. PubMed ID: 16246051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
